Correlation between periostin and SNCG and esophageal cancer invasion, infiltration and apoptosis

OBJECTIVE@#To investigate the correlation between periostin and SNCG and esophageal cancer invasion, infiltration and apoptosis.@*METHODS@#A total of 78 cases esophageal surgical resection specimens were collected, expression of periostin and SNCG in esophageal cancer were detected. Effect of periostin and SNCG in esophageal carcinoma invasion and infiltration was analyzed.@*RESULTS@#The upregulated rate of periostin had significant difference in esophageal cancer tissues (39.74%), adjacent tissues (17.86%) and normal tissues (0.00%); The positive expression rates of SNCG had significant difference in esophageal cancer tissues (61.54%), adjacent tissues (32.14%) and normal tissues (1.96%); The upregulated rate of periostin had a significant correlation with lymph node metastasis, adventitia invasion, TNM stage; The positive expression rates of SNCG had a significant correlation with differentiation degree, lymph node metastasis, adventitia invasion, TNM stage; Apoptosis index of the positive of expression of SNCG of esophageal cancer tissue (4.541±2.267) was significantly lower than that of the negative expression (7.316±2.582) (P<0.05).@*CONCLUSIONS@#SNCG may play an important role in invasion, infiltration and apoptosis of esophageal cancer and serve as target spots in the targeted therapy of esophageal cancer.

Clinical observation of paclitaxel liposome combined with nedaplatin in treatment of advanced esophageal cancer / 肿瘤

Objective: To evaluate the efficacy and toxicity of paclitaxel liposome combined with nedaplatin as first-line chemotherapy for patients with advanced esophageal cancer. Methods: A total of 42 patients with pathologically confirmed advanced esophageal cancer were recruited into this study. On day 1, the patients were intravenously infused with 135 mg/m2 paclitaxel liposome followed by nedaplatin 80 mg/m2. This chemotherapy regimen was repeated every three weeks until the documented disease progression, unacceptable toxicity or patients' refusal. All patients received at least two cycles of chemotherapy, and the short-term response and toxicity were evaluated every two cycles. The patients were followed-up, and the survival was analyzed. The intention-to-treat analysis was applied. Results: Forty-one of the 42 patients were assessable for short-term response. The overall response rate was 40.5% (17/42) including complete response in one patient (2.4%) and partial response in 16 patients (38.1%). Fourteen patients (33.3%) received stable disease, and ten patients received progressive disease (23.8%). The overall response rates of chemotherapy in naive patients (n =18) and relapsed patients (n=24) were 55.6% and 29.2%, respectively. The estimate of overall one-year survival rate was 42.6%. The median time to progression and the median overall survival time were 6.3 months and 11.3 months, respectively. The common adverse reaction was hematologic toxicity including 7 patients with grade 3/4 neutropenia and 4 patients with grade 3 thrombocytopenia. The main non-hematologic toxicity was grade 3/4 vomiting in 3 patients(7.3%). No toxicity-related death occurred. Conclusion: The combined therapy of paclitaxel liposome and nedaplatin is effective and well tolerated in patients with advanced esophageal cancer. Copyright© 2011 by TUMOR.